Rapt Therapeutics Inc.
RAPT Therapeutics Acquired by GlaxoSmithKline in $1.75B Deal
Summary
RAPT Therapeutics, Inc. has been acquired by GlaxoSmithKline LLC in a $1.75 billion deal, completing a tender offer where approximately 93.36% of RAPT's shares were tendered. The merger, which became effective on March 3, 2026, resulted in RAPT becoming a wholly owned subsidiary of GlaxoSmithKline. The acquisition led to significant changes in RAPT's board and executive officers, with all existing directors resigning and new directors appointed. The company's certificate of incorporation and bylaws were also amended. RAPT's common stock was delisted from Nasdaq, and the company intends to terminate its registration under the Securities Exchange Act of 1934.
Profitelligence Alerts
Get alerts for RAPT
Be first to know when Rapt Therapeutics Inc. files with the SEC.
Filing Categories
Advertisement
About Rapt Therapeutics Inc.
Rapt Therapeutics Inc. is a biotechnology firm focused on the discovery, development, and commercialization of oral small molecule therapies for oncology and inflammatory diseases. Its primary mission is to create novel treatments by harnessing its proprietary drug discovery platform, which targets key pathways responsible for the progression of these complex conditions. Rapt Therapeutics is notably advancing its development of selective inhibitors for immune checkpoint inhibitors within the broader cancer treatment landscape, potentially enhancing the efficacy of existing therapies. The company's pipeline includes multiple drug candidates tailored for specific types of cancer and chronic inflammatory disorders, underscoring its commitment to addressing unmet medical needs. By concentrating efforts on innovative approaches that modulate immune and inflammatory responses, Rapt Therapeutics plays a significant role in shaping the future of precision medicine in the biopharmaceutical industry. Founded in 2015 and leveraging advanced scientific insights, Rapt Therapeutics represents an important component of the biotech sector's efforts to push boundaries in disease treatment and improve patient outcomes.
Official SEC Documents
Advertisement